ClinicalTrials.gg
RecruitingNCT06157840Updated Sep 28, 2026

Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD

An interventional study of mHealth application and sleep health education and Simplified mHealth application and sleep health education in Opioid Use Disorder and Poor Quality Sleep, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Sep 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Opioid-Related Disorders by Medical University of South Carolina — 7 open to participants now, 7 under way, none of them phase 3. Opioid-Related Disorders · Medical University of South Carolina.

Planned enrollment
6th of 15
40 · median 24
Started
2025
with 2 others
No phase
8 of 15
6 open now
Registered
8th of 15
by date

Among the 15 studies in Opioid-Related Disorders by Medical University of South Carolina, this one is the 6th largest by planned enrollment, is one of 3 that started in 2025, is one of 8 with no phase, and was the 8th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

7 of the 15 studies in Opioid-Related Disorders by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Opioid-Related Disorders by Medical University of South Carolina, or all of them as a file.
02

Study summary

This study is to develop and test a medical health application based on cognitive behavioral therapy for insomnia and augmented with other evidence-based sleep interventions that address common sleep-related problems in opioid use disorder. An initial program will be built utilizing input from persons beginning medications for opioid use disorders.

Read the detailed description

This pilot randomized controlled trial will assess the feasibility and acceptability of an evidence-based behavioral sleep intervention delivered via a mHealth app to individuals initiating treatment with medications for opioid use disorder. Additional outcomes include changes in sleep disturbance over the course of the 6-week intervention. Participants (N=40, 20 per group) will be randomized to download the mHealth app to their smartphones and complete the intervention within 6 weeks. The control group will receive a simplified version of the app with sleep hygiene instructions. Both groups will complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity. At the end of the 6th week, they will complete an online series of questionnaires, including validated feasibility/acceptability measures and measures of insomnia severity.

03

Conditions studied

  • Opioid Use Disorder
  • Poor Quality Sleep
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • No experience of withdrawal symptoms in past 2 weeks
  • Being stabilized on buprenorphine

    1. Initiated buprenorphine in past 3 months
    2. Modified buprenorphine dose in past 3 months (e.g., reducing dose with goal of transitioning to vivitrol)
  • Currently experiencing sleep disturbance (PSQI > 5)
  • Able to read and understand English
  • Owns an Android or iOS smartphone
  • At least 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Current psychotic symptoms
  • Current active suicidal ideation
  • Severe visual impairment
  • Current use of benzodiazepines
  • Current severe SUD other than OUD (i.e., > 5 criteria met for any other SUD type per )
  • Peripartum women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    mHealth application

    Study participants, while being stabilized on buprenorphine, will download and engage with the developed mHealth application, completing daily electronic sleep diaries for the next 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.

    Device: mHealth application and sleep health education

  • Experimental
    Control Group

    Participants in the control group will receive a simplified version of the app with sleep hygiene (SH) instructions and will be required to complete daily electronic sleep diaries for the next 6 weeks. The SH condition will utilize the same application and entail the same daily and weekly logs, but with the didactic material replaced by detailed education about SH strategies. Each week, participants will be asked to complete a brief assessment of their experiences from the previous week and their current insomnia severity.

    Device: Simplified mHealth application and sleep health education

Interventions

  • DevicemHealth application and sleep health education

    Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity

  • DeviceSimplified mHealth application and sleep health education

    Study participants will download the mHealth app to their smartphones and complete the intervention within 6 weeks. They will receive a simplified version of the app with sleep hygiene instructions and will be required to complete daily electronic sleep diaries for the following 6 weeks. Each week, they will be asked to complete a short assessment of their experiences from the previous week and their current insomnia severity.

06

What researchers measure

Primary outcomes

  1. Enrollment feasibility/acceptability benchmark of at least 30 persons completing entire study period - Enrollment and retention percentages

    To achieve a minimum enrollment and retention percentage of 75% throughout the 6-week investigation period.

    Time frame: 6 weeks following enrollment

  2. Protocol adherence feasibility/acceptability benchmarks of participants completing modules and sleep diaries each week - Engagement

    Completing at least one module per week, submitting a minimum of four sleep diaries per week, and implementing stimulus control and sleep restriction on at least 90% of nights.

    Time frame: 6 weeks following enrollment

  3. mHealth App Usability Questionnaire

    Validated measure of mobile app usability with 3 sections: Ease of use/satisfaction, system information arrangement, and usefulness

    Time frame: 6 weeks following enrollment

Secondary outcomes

  1. Pittsburgh Sleep Quality Index

    Validated measure of difficulty falling and staying asleep and subsequent daytime function

    Time frame: At enrollment and 6 weeks following enrollment

  2. Structured Clinical Interview for Sleep Disorders - Revised Edition

    Assessment for sleep disorders based on the DSM-5

    Time frame: At enrollment and 6 weeks following enrollment

  3. Insomnia Severity Index

    Global sleep quality; the most common self-reported sleep measure

    Time frame: At enrollment and 6 weeks following enrollment

  4. Daily Sleep Diary - Sleep Onset Latency

    Subjective sleep onset latency (time to fall asleep)

    Time frame: Through study completion of 6 weeks

  5. Daily Sleep Diary - Wake-time After Sleep

    Subjective time awake after sleep onset

    Time frame: Through study completion of 6 weeks

  6. Daily Sleep Diary - Total Sleep Time

    Subjective total sleep time

    Time frame: Through study completion of 6 weeks

  7. Daily Sleep Diary - Sleep Efficiency

    Subjective sleep efficiency

    Time frame: Through study completion of 6 weeks

Other outcomes

  1. MOUD and drug use

    Self-reported checklist

    Time frame: Through study completion of 6 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 15 months is below that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2023
First posted
Dec 6, 2023
StartActual
Aug 25, 2025
Primary completionEst.
Dec 15, 2026was Sep 2026
CompletionEst.
Dec 31, 2026was Sep 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 15, 2026→Dec 15, 2026
Sep 28, 2026
Study completion
Sep 30, 2026→Dec 31, 2026
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Primary completion Sep 15, 2026→Dec 15, 2026
    Study completion Sep 30, 2026→Dec 31, 2026
    + 3 other changes: verification date, responsible party and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06157840
Responsible party
Sponsor
First posted
Dec 6, 2023
Start date
Aug 25, 2025
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 28, 2026

Study contacts

Allison K Willkerson, Ph.D.
Contact
wilkersa@musc.edu
843-792-4636
Jacelyn Lane
Contact
lanejac@musc.edu
Allison K Wilkerson, Ph.D.
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion